No Result
View All Result
SUBSCRIBE
The Upper Middle
  • All News
    • Business
    • Commentary
    • Community
    • Culture
    • Education
    • Events
    • Family
    • Food & Drink
    • Lifestyle & Fitness
    • Local News
    • Real Estate
  • Business Directory
The Upper Middle
  • All News
    • Business
    • Commentary
    • Community
    • Culture
    • Education
    • Events
    • Family
    • Food & Drink
    • Lifestyle & Fitness
    • Local News
    • Real Estate
  • Business Directory
No Result
View All Result
SUBSCRIBE
The Upper Middle
No Result
View All Result

FDA Approves First Systemic Treatment for Alopecia Areata

  • June 15, 2022
  • theumphx
  • The Upper Middle

This week, the U.S. Food and Drug Administration approved Olumiant (baricitinib) oral tablets to treat adult patients with severe alopecia areata, a disorder that often appears as patchy baldness and affects more than 300,000 people in the U.S. each year. Today’s action marks the first FDA approval of a systemic treatment, which treats the entire body rather than a specific location for alopecia areata.

“Access to safe and effective treatment options is crucial for the significant number of Americans affected by severe alopecia,” said Kendall Marcus, M.D., director of the Division of Dermatology and Dentistry in the FDA’s Center for Drug Evaluation and Research. “Today’s approval will help fulfill a significant unmet need for patients with severe alopecia areata.”

Alopecia areata, commonly referred to as just alopecia, is an autoimmune disorder in which the body attacks its own hair follicles, causing hair to fall out, often in clumps. Olumiant is a Janus kinase (JAK) inhibitor which blocks the activity of one or more of a specific family of enzymes, interfering with the pathway that leads to inflammation.

The efficacy and safety of Olumiant in alopecia areata was studied in two randomized, double-blind, placebo-controlled trials Trial AA-1 and Trial AA-2 with patients who had at least 50% scalp hair loss as measured by the Severity of Alopecia Tool for more than six months. Patients in these trials received either a placebo, 2 milligrams of Olumiant, or 4 milligrams of Olumiant every day. The primary measurement of efficacy for both trials was the proportion of patients who achieved at least 80% scalp hair coverage at week 36.

In Trial AA-1, 22% of the 184 patients who received 2 milligrams of Olumiant and 35% of the 281 patients who received 4 milligrams of Olumiant achieved adequate scalp hair coverage, compared to 5% of the 189 patients who received a placebo. In Trial AA-2, 17% of the 156 patients who received 2 milligrams of Olumiant and 32% of the 234 patients who received 4 milligrams of Olumiant achieved adequate scalp hair coverage, compared to 3% of the 156 patients who received a placebo.

The most common side effects associated with Olumiant include: upper respiratory tract infections, headache, acne, high cholesterol (hyperlipidemia), increase of an enzyme called creatinine phosphokinase,  urinary tract infection,  liver enzyme elevations, inflammation of hair follicles (folliculitis), fatigue, lower respiratory tract infections, nausea, genital yeast infections (Candida infections), anemia, low number of certain types of white blood cells (neutropenia), abdominal pain, shingles (herpes zoster) and weight increase.

Olumiant was originally approved in 2018. It is approved as a treatment for certain adult patients with moderately to severely active rheumatoid arthritis. Olumiant is also approved for the treatment of COVID-19 in certain hospitalized adults.

Sponsored Ad

RECENT NEWS

New Lydia’s Kitchen & Market Opens with Laid-Back Elegance at The Frederick

Weekend Wellness at the Arcadia Improvement Club

Summer Pool Safety in Arizona: A Guide for Families

Where to Celebrate Father’s Day in Phoenix

Uptown Plaza: Phoenix Landmark Updated with Mid-Century Modern Charm

Le Petit Chef at the Arizona Biltmore Delivers a Stunning 3D Dining Experience in Phoenix

Next Post
Sunrise Park Resort Opens Friday

New Pay Structure Makes Phoenix Police Officers Highest Paid Arizona Law Enforcement Agency

Fose + McKay Fose + McKay Fose + McKay
The Upper Middle Phoenix
The Upper Middle Phoenix (The UM) is your go-to source for local news, events, business updates, and culture in Arcadia, North Central Phoenix, and Biltmore. We also cover Paradise Valley and Downtown Phoenix, bringing you the latest on food & drink, real estate, outdoor activities, and community happenings.
Connecting the Upper Middle Neighborhoods of Phoenix - Arcadia, Biltmore, North Central

Subscribe To Our Newsletter

SUBSCRIBE

©2025 The Upper Middle 1801 East Camelback Road, Suite 201, Phoenix, AZ 85016 / 602.222.4700 / [email protected] 

Max Fose – Publisher | Privacy Policy | Advertise With Us | Media Kit | About The Upper Middle Phoenix

No Result
View All Result
  • Home
  • All News
    • Business
    • Commentary
    • Community
    • Culture
    • Education
    • Events
    • Family
    • Food & Drink
    • Lifestyle & Fitness
    • Local News
    • Real Estate
  • Business Directory
Connecting the Upper Middle Neighborhoods of Phoenix - Arcadia, Biltmore, North Central

©2025 The Upper Middle 1801 East Camelback Road, Suite 201, Phoenix, AZ 85016 / 602.222.4700 / [email protected]